5:34 PM
 | 
Apr 10, 2013
 |  BC Extra  |  Company News

Pfizer's palbociclib gets breakthrough designation

Pfizer Inc. (NYSE:PFE) said FDA granted breakthrough drug designation to palbociclib ( PD-0332991) to treat breast cancer. A spokesperson for the pharma said the oral small molecule cyclin dependent kinase 4 (CDK4) and

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >